MARKET

REPH

REPH

Recro Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.15
+0.12
+1.71%
After Hours: 7.12 -0.03 -0.38% 16:05 04/02 EDT
OPEN
7.05
PREV CLOSE
7.03
HIGH
7.31
LOW
7.00
VOLUME
603.78K
TURNOVER
--
52 WEEK HIGH
19.21
52 WEEK LOW
5.47
MARKET CAP
167.70M
P/E (TTM)
37.67
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average REPH stock price target is 18.25 with a high estimate of 23.00 and a low estimate of 14.00.

EPS

REPH News

More
  • Mid-Day Market Update: Dow Jumps Over 400 Points; Plus Therapeutics Shares Spike Higher
  • Benzinga · 3d ago
  • OMI, PSTV, GRPN and WMC among midday movers
  • Seeking Alpha - Article · 3d ago
  • Edited Transcript of REPH earnings conference call or presentation 4-Mar-20 1:00pm GMT
  • Thomson Reuters StreetEvents · 03/26 09:39
  • Baudax Bio plans $25M stock sale to fund first product launch
  • American City Business Journals · 03/25 17:28

Industry

Pharmaceuticals
+2.64%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About REPH

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
More

Webull offers kinds of Recro Pharma Inc stock information, including NASDAQ:REPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPH stock news, and many more online research tools to help you make informed decisions.